Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 141-147

  Alfa wali, M ^a   Allen mersh, T ^a   Antoniou, A ^a,b   Tait, D ^c   Newsom Davis, T ^d   Gazzard, B ^d   Nelson, M ^d   Bower, M ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Anal cancer; CD4 cell count; Chemoradiotherapy; HIV

Indexed keywords

CAPECITABINE; FLUOROURACIL; MITOMYCIN C; RITONAVIR;

ADULT; AGED; ANEMIA; ANUS CANCER; ANUS FISSURE; ANUS FISTULA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHEMORADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY TUBULE NECROSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROCTITIS; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 84855166105     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr050     Document Type: Article

References (42)

1. Melbye M, Cote TR, Kessler L et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994; 343: 636- 639.
2. Frisch M, Melbye M, Moller H. Trends in incidence of anal cancer in Denmark. BMJ 1993; 306: 419-422.
3. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
4. Palefsky JM, Holly EA, Ralston ML et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12: 495-503.
5. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500-1510.
6. Patel P, Hanson DL, Sullivan PS et al. Incidence of types of cancer among HIV infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148: 728-736.
7. Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
8. Bower M, Powles T, Newsom-Davis T et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37: 1563-1565.
9. Crum-Cianflone NF, Hullsiek KH, Marconi VC et al. Anal cancers among HIVinfected persons: HAART is not slowing rising incidence. AIDS 2010; 24: 535-543.
10. Lorenz HP, Wilson W, Leigh B et al. Squamous cell carcinoma of the anus and HIV infection. Dis Colon Rectum 1991; 34: 336-338.
11. Svensson C, Kaigas M, Lidbrink E, Goldman S. Carcinoma of the anal canal in a patient with AIDS. Acta Oncol 1991; 30: 986-987.
12. Peddada AV, Smith DE, Rao AR et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1997; 37: 1101-1105.
13. Hoffman R, Welton ML, Klencke B et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999; 44: 127-131.
14. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
15. Gazzard BG, Anderson J, Babiker A et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
16. James R, Meadows H, Wan S. ACT II: the second UK phase III anal cancer trial. Clin Oncol (R Coll Radiol) 2005; 17: 364-366.
17. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
19. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIVpositive patients with anal squamous cell carcinoma. Dis Colon Rectum 2001; 44: 506-512.
20. Vatra B, Sobhani I, Aparicio Tet al. [Anal canal squamous-cell carcinomas in HIV positive patients: clinical features, treatments and prognosis]. Gastroenterol Clin Biol 2002; 26: 150-156.
21. Oehler-Janne C, Huguet F, Provencher Set al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26: 2550-2557.
22. Piketty C, Selinger-Leneman H, Grabar Set al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22: 1203-1211.
23. Abramowitz L, Mathieu N, Roudot-Thoraval Fet al. Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther 2009; 30: 414-421.
24. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008; 26: 474-479.
25. Diamond C, Taylor TH, Aboumrad Tet al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32: 314-320.
26. Kim JH, Sarani B, Orkin BAet al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum 2001; 44: 1496-1502.
27. Chadha M, Rosenblatt EA, Malamud Set al. Squamous-cell carcinoma of the anus in HIV-positive patients. Dis Colon Rectum 1994; 37: 861-865.
28. Holland JM, Swift PS. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology 1994; 193: 251-254.
29. Blazy A, Hennequin C, Gornet JMet al. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum 2005; 48: 1176-1181.
30. Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2006; 66: 206-211.
31. Wexler A, Berson AM, Goldstone SEet al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008; 51: 73-81.
32. Seo Y, Kinsella MT, Reynolds HLet al. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009; 75: 143-149.
33. Barriger RB, Calley C, Cardenes HR. Treatment of anal carcinoma in immunecompromised patients. Clin Transl Oncol 2009; 11: 609-614.
34. Hogg ME, Popowich DA, Wang ECet al. HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum 2009; 52: 891-897.
35. Fraunholz I, Weiss C, Eberlein Ket al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys 2010; 76: 1425-1432.
36. Northover J, Glynne-Jones R, Sebag-Montefiore Det al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010; 102: 1123-1128.
37. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348: 1049-1054.
38. Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005; 40: 451-455.
39. Bower M, McCall-Peat N, Ryan Net al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104: 2943-2946.
40. den Hartigh J, McVie JG, van Oort WJ, Pinedo HM. Pharmacokinetics of mitomycin C in humans. Cancer Res 1983; 43: 5017-5021.
41. Wichmann MW, Meyer G, Adam Met al. Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. Dis Colon Rectum 2003; 46: 875-887.
42. Powles T, Imami N, Nelson Met al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531-536.